Curatis Holding AG (0QNS.L)

0.0154 +0.0154 (+84.00%) As of 05:07PM BST. Market open.

Curatis Holding AG

Technologiepark Basel
Hochbergerstrasse 60C
Basel 4057
Switzerland
41 61 633 29 71
https://www.kinarus.com

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Alexander Bausch MTE (IMD), Ph.D.	CEO & Vice Chairman	291.38k	N/A	1962
Dr. Matthew Wright	COO & Head of Research	236.16k	N/A	N/A
Ms. Claudia Berger	Chief Clinical Devel. Officer	136.73k	N/A	N/A
Dr. Thierry Fumeaux M.B.A., M.D.	Chief Medical Officer	136.73k	N/A	N/A
Stephane Pinto	Head of Investor Relations	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 mitogen-activated protein kinase inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company was founded in 2017 and is based in Basel, Switzerland.

Corporate governance

Curatis Holding AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.